TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00152763

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Cardiac Care (UCC)
Description: Usual cardiac care (UCC) was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Cardiac Care (UCC)
Description: Usual cardiac care (UCC) was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed.
Study: NCT02500212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENVARSUS®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAGRAF®
Study: NCT02270359

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CMR
Description: Cardiac magnetic resonance imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (smelling)

Intervention type: DRUG
Group type: OTHER
Intervention: contrast agent, Gadolinium
Description: Gadolinium contrast will be administered during CMR
Study: NCT00439166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline
Description: capsule, 100 mg, b.i.d., daily for 1 year
Study: NCT02622763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tolerogenic Dendritic Cells
Description: Intralesional administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tolerogenic Dendritic Cells
Description: Intralesional administration
Study: NCT04627532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07304814
Description: Participants will receive PF-07304814

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will recieve placebo
Study: NCT02111746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Participants will receive 266mg of liposomal bupivicaine (equivalent of one 1.3% 20ml vial of EXPAREL®) diluted in 60ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrochloride
Description: Participants will receive 125mg of bupivacaine hydrochloride (equivalent of one 0.25% 50ml or five 0.25% 10ml vials ) diluted in 30ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patient Controlled Analgesia (PCA)
Description: Patients will have access to the standard Patient Controlled Analgesia (PCA) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10 minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs. Patients will receive PCA until the third postoperative day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient Controlled Analgesia (PCA)
Description: Patients will have access to the standard Patient Controlled Analgesia (PCA) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10 minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs. Patients will receive PCA until the third postoperative day
Study: NCT01909323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maltitol 85% / FOS15%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maltitol alone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maltitol 68% / FOS 32%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maltitol 50% / FOS 50%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FOS alone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00199797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin was administered at 85 mg/m2 on day 2 of every 2 week regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: The dose of 5-FU was 400 mg/m2 IV bolus followed by continuous IV infusion at 600 mg/m2 over 22 hours on day 2 and day 3 of every 2 week regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin was administered at a dose of 200mg/m2 on day 2 and day 3 of every 2 week regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: huA33
Description: huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2.
Study: NCT01685489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, PSK®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel, Placebo
Study: NCT02027597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attack of the S. Mutans
Description: A research assistant led groups of students through the Attack of the S. Mutans exhibit. All participants played all the games and viewed all the graphical content of the exhibit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attack of the S. Mutans
Description: A research assistant led groups of students through the Attack of the S. Mutans exhibit. All participants played all the games and viewed all the graphical content of the exhibit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up
Description: This group experienced the Attack of the S. Mutans! exhibit and 3 doses of follow-up booster content at a web site.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SnowWorld
Description: SnowWorld is a 3D first-person-shooter game developed by Firsthand Technology. In SnowWorld, the player shoots snowballs at penguins, polar bears, and other features of a frozen landscape. The game is designed to help burn victims cope with pain, and has no oral health messages.
Study: NCT03376971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo lung biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00465803

Intervention type: DRUG
Group type: OTHER
Intervention: Travoprost 0.004%/timolol 0.5% ophthalmic solution
Description: One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months using the Dosing Aid

Intervention type: DRUG
Group type: OTHER
Intervention: Travoprost ophthalmic solution, 0.004%
Description: One drop in the study eye(s) once daily at 8 PM for twelve months using the Dosing Aid

Intervention type: DRUG
Group type: OTHER
Intervention: Timolol maleate ophthalmic solution, 0.5%
Description: One drop in the study eye(s) once daily at 8 AM or twelve months using the Dosing Aid
Study: NCT03086928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lava ultimate
Description: resin nano ceramic material

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E.max cad
Description: Lithium disilicate glass ceramic
Study: NCT02370589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Base Dose EBOV GP Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Base Dose EBOV GP Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Base Dose EBOV GP Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2x Base Dose EBOV GP Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2x Base Dose EBOV GP Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2x Base Dose EBOV GP Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4x Base Dose EBOV GP Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4x Base Dose EBOV GP Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4x Base Dose EBOV GP Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8x Base Dose EBOV GP Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8x Base Dose EBOV GP Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8x Base Dose EBOV GP Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M Adjuvant
Study: NCT01684098

Intervention type: DRUG
Group type: OTHER
Intervention: Tc 99m EC20
Study: NCT03134846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800CW
Description: Pre-operatively administration of Cetuximab-IRDye800CW for intra operative margin assessment using a fluorescent antibody-based optical tracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800CW
Description: Pre-operatively administration of Cetuximab-IRDye800CW for intra operative margin assessment using a fluorescent antibody-based optical tracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800CW
Description: Pre-operatively administration of Cetuximab-IRDye800CW for intra operative margin assessment using a fluorescent antibody-based optical tracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800CW
Description: Pre-operatively administration of Cetuximab-IRDye800CW for intra operative margin assessment using a fluorescent antibody-based optical tracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800CW
Description: Pre-operatively administration of Cetuximab-IRDye800CW for intra operative margin assessment using a fluorescent antibody-based optical tracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800CW
Description: Pre-operatively administration of Cetuximab-IRDye800CW for intra operative margin assessment using a fluorescent antibody-based optical tracer
Study: NCT01752881

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (split virion, inactivated)
Description: AdimFlu-S, Inactivated Influenza Vaccine Trivalent Types A and B (Split) Formulation 2012-2013~Dosage: 0.5mL/per syringe~Administration route: Intramuscular Injection, once

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimFlu-S
Study: NCT02078895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Peri-Ureteral and Intradetrusor Injection of Botulinum Toxin Type A
Study: NCT04306159

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcostal TAP
Description: Subcostal transversus abdominis plane block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified RSB
Description: Rectus Sheath Block under the guidance of surgical incision

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: General anesthesia
Description: Traditional general anesthesia management
Study: NCT03895606

Intervention type: OTHER
Intervention: Data collection
Description: This study is an observational study collecting perioperative data. There is no intervention regarding this study.
Study: NCT00029536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Progesterone Lozenges
Description: 200mg Progesterone Lozenges

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Progesterone Lozenges
Description: 200mg Progesterone Lozenges

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo Lozenges
Description: Matched Placebo Lozenges

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo Lozenges
Description: Matched Placebo Lozenges
Study: NCT02170090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1250mg/m2
Study: NCT01730534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Oral dose (od)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Oral dose (od)
Study: NCT02990585

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Back school

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Back school
Study: NCT04311749

Intervention type: GENETIC
Intervention: Expanded panel cell free DNA testing (non-invasive prenatal testing)
Description: Maternal blood sampling

Intervention type: GENETIC
Intervention: Placental biopsy
Description: Post-delivery placental sampling
Study: NCT00439166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline
Description: capsule, 100 mg, b.i.d., daily for 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: capsule, 300mg, o.d., daily for 11 months (administration starts in 2nd month of trial)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: capsule, 300mg, o.d., daily for 11 months (administration starts in 2nd month of trial)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matched to doxycycline
Description: Doxycycline-matched - blue capsule, b.i.d.,daily for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to doxycycline
Description: Doxycycline-matched - blue capsule, b.i.d.,daily for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matched to Rifampin
Description: Rifampin-matched - red capsule, o.d., daily for 11 months starting at month 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to Rifampin
Description: Rifampin-matched - red capsule, o.d., daily for 11 months starting at month 2.
Study: NCT04953013

Intervention type: DRUG
Intervention: sodium bicarbonate
Description: Drug exposure
Study: NCT00816387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fallopian tube sperm perfusion
Description: Patients are treated with fallopian tube sperm perfusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine insemination using standard catheter
Description: Patients are treated with standard intrauterine insemination
Study: NCT02999711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500
Description: REGN3500 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500
Description: REGN3500 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study: NCT00144872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine will be given as chewable dispersible tablets with dosing strengths of 2, 5, 25, and 100 milligrams.
Study: NCT00512551

Intervention type: PROCEDURE
Intervention: Tumor Biopsies
Description: Biopsies of the cervical tumor performed first before any treatment is given, and the second about 48 hours after radiation treatment has began.
Study: NCT00902889

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stimulation
Description: 6 weeks stimulation with GPI (lower caudal two contacts), 4 weeks wash-out, 6 weeks stimulation GPE (upper cranial two contacts)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stimulation
Description: 6 weeks stimulation with GPE (upper cranial two contacts), 4 weeks wash-out, 6 weeks stimulation with GPI (lower caudal two contacts)
Study: NCT04653636

Intervention type: OTHER
Intervention: Arthrographic distension
Description: The treatment consists in one to three shoulder joint capsule arthrographic distension. It consists after local anesthesia, in an injection under pressure of xylocaine 1% and physiological serum in the glenohumeral joint associated with an ampoule of corticosteroids (Betamethasone or Triamcinolone hexacetonide ) at the end of the operation.~* first arthrographic distension is performed under scopic guidance~* second and/or third arthrographic distension are performed under ultrasound guidance

Intervention type: OTHER
Intervention: Immediate joint mobilization
Description: This procedure was associated with intensive (immediate mobilization, recovery of maximum amplitudes by the physiotherapist and on arthro-motor).~Physical treatment aimed at rapid amplitude gain and is started immediately after the arthrographic distension, under the effect of local anesthesia. It is at best continued daily at a rate of 2 to 8 hours per day for one to 2 weeks. Depending on the effect obtained on pain and the daily progression of rehabilitation, arthrographic distension may be repeated once or twice during the mobilization period.
Study: NCT03545815

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-mesothelin CAR-T cells
Description: Cells will be infused on day 0.
Study: NCT03354637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATI-50002 high dose
Description: Topical solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATI-50002 low dose
Description: Topical solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical solution
Study: NCT00569803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: belatacept
Description: single dose, 116 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: belatacept
Description: single dose, 116 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: belatacept
Description: single dose, 116 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: belatacept
Description: single dose, 116 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: belatacept
Description: single dose, 116 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: belatacept
Description: single dose, 116 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: belatacept
Description: single dose, 116 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)
Study: NCT01313611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab + bendamustine
Description: Induction phase: rituximab and bendamustine on Day 1, Bendamustine on Day 2, Rituximab on Day 8, Rituximab on Day 15, Rituximab on Day 22, bendamustine on Day 29, Bendamustine on Day 30
Study: NCT01324479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Study: NCT01993823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G238
Description: Five drops into the ear canal twice daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole
Description: Five drops into the ear canal twice daily for 14 days
Study: NCT03826589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: an anti-programmed cell death ligand 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: a tyrosine kinase inhibitor that also inhibits VEGF receptor 1-3, c-KIT and PDGFR
Study: NCT00599989

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intracavitary balloon brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton beam radiation therapy
Study: NCT01965158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Naldemedine 0.2 mg tablet taken orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken orally once a day
Study: NCT01305746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-623
Description: High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-623
Description: Low dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-623
Description: High dose given subcutaneously once every 4 weeks until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
Study: NCT03975426

Intervention type: PROCEDURE
Intervention: open reduction and internal fixation with fixation by absorbable screws
Description: Group A received conservative therapy involving bed rest with the affected lower extremity positioned with the hip and knee in flexion to ensure minimal tension of the muscles attached to the ASIS avulsion fracture. Group B received open reduction and internal fixation with fixation by absorbable screws.